ValuEngine downgraded shares of PURE Bioscience (OTCMKTS:PURE) from a hold rating to a sell rating in a research note released on Tuesday.
PURE Bioscience (PURE) opened at 1.00 on Tuesday. PURE Bioscience has a 1-year low of $0.75 and a 1-year high of $1.36. The company’s market capitalization is $62.71 million. The company has a 50-day moving average of $1.18 and a 200-day moving average of $1.07.
PURE Bioscience Company Profile
PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.